houseStanding
Energy and Commerce Committee
- Referred To
- Markup By
- Reported By
← Back to federal legislation0 ratings0 comments Official committee record ↗
H.R. 8205Became law
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Introduced: Apr 6, 2026
Latest action date: Nov 3, 2026
Latest development
Became Public Law No: 119-138.
Civixly approval
No ratings yet
Not enough ratings yet. Public approval appears at 5+ ratings.
Your view
- Congress
- 119th Congress
- Introduced
- Apr 6, 2026
- Recorded roll calls
- 0
Status detail: Congress.gov records that the measure became law.
Plain-language overview
What this bill does
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
This act reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.
The act reauthorizes
- grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
- grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
- a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.
Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs.
Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.
Official summary from Congress.gov · checked Nov 5, 2026.
Civixly topics
What this legislation is about
Civixly topics make federal and state legislation comparable. They are derived from the official CRS policy area and legislative subjects.
Official CRS policy area
Health
View 11 official legislative subjects
Department of Health and Human ServicesDrug therapyFood and Drug Administration (FDA)Government information and archivesHealth programs administration and fundingInternet, web applications, social mediaMedical researchNational Institutes of Health (NIH)Neurological disordersPublic-private cooperationResearch administration and funding
Committee activity
Committees and subcommittees that received, reviewed, marked up, or reported this legislation.
Official committee record ↗
houseSubcommittee
Health Subcommittee
- Referred to
- Markup by
- Reported by
Amendments
Proposed changes to this measure, with their latest official outcome or action from Congress.gov.
No amendments are listed for this measure.
Checked against Congress.gov Nov 5, 2026.
Action timeline
Newest action first. Action language comes from the official Congress.gov record.
View full action timeline29 actions
Signed by President.
PresidentLibrary of CongressSigned by President.
BecameLawLibrary of CongressBecame Public Law No: 119-138.
PresidentLibrary of CongressBecame Public Law No: 119-138.
BecameLawLibrary of CongressPresented to President.
FloorHouse floor actionsPresented to President.
PresidentLibrary of CongressMessage on Senate action sent to the House.
FloorSenatePassed/agreed to in Senate: Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
FloorLibrary of CongressPassed Senate without amendment by Voice Vote. (consideration: CR S5120)
FloorSenateReceived in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
CalendarsSenateMotion to reconsider laid on the table Agreed to without objection.
FloorHouse floor actionsPassed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
FloorLibrary of CongressOn motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
FloorHouse floor actionsConsidered as unfinished business. (consideration: CR H5159)
FloorHouse floor actionsAt the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
FloorHouse floor actionsDEBATE - The House proceeded with forty minutes of debate on H.R. 8205.
FloorHouse floor actionsConsidered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)
FloorHouse floor actionsMr. Guthrie moved to suspend the rules and pass the bill, as amended.
FloorHouse floor actionsReported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
CommitteeHouse floor actionsReported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
CommitteeLibrary of CongressPlaced on the Union Calendar, Calendar No. 637.
CalendarsHouse floor actionsCommittee Consideration and Mark-up Session Held
CommitteeHouse committee actionsOrdered to be Reported (Amended) by the Yeas and Nays: 46 - 0.
CommitteeHouse committee actionsForwarded by Subcommittee to Full Committee by Voice Vote.
CommitteeHouse committee actionsSubcommittee Consideration and Mark-up Session Held
CommitteeHouse committee actionsIntroduced in House
IntroReferralLibrary of CongressReferred to the Subcommittee on Health.
CommitteeHouse committee actionsIntroduced in House
IntroReferralLibrary of CongressReferred to the House Committee on Energy and Commerce.
IntroReferralHouse floor actions
Roll-call votes
Recorded House and Senate votes connected to this bill. Your representatives appear first when available.
No connected roll-call votes are currently available for this bill.
Discussion
0 comments across 0 threads
Sign in to join the discussion.Comments are publicly visible.
Loading comments...